PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
There are three arms to this study (A, B and C) The purpose of this research study during Arm
A is to see how much of PF-00299804 gets into the brain tumor. For many brain tumors, one
reason that chemotherapy drugs might not be effective is that the drug may not be able to get
into the brain tumor and kill the cancer cells. We will determine how much PF-00299804 gets
into the brain tumor by obtaining a sample of the tumor from the surgery that the participant
already has scheduled. The purpose of this research study during Arm B and C, is to determine
how well PF-00299804 works in killing cancer cells. PF-00299804 works by binding to specific
proteins found on the surface of some cancer cells that promote a growth signal. Blocking
this signal from reaching its target on the cancer cells may slow or stop the cancer from
growing.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Henry Ford Hospital Pfizer